![Page 1: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/1.jpg)
Analytical study on certain drugs which treat brain
agency and deterioration.
![Page 2: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/2.jpg)
This thesis consists of four parts:- PartI:Stability indicating methods for the
determination of Pyritinol dihydrochloride. Part II: Stability indicating colorimetric method for
the determination of piracetam. Part III : Stability indicating colorimetric
method for the determination of meclophenoxate hydrochloride.
Part IV :Stability indicating methods for the determination of vincamine in presence of its degradation product.
![Page 3: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/3.jpg)
Part I :Stability indicating methods for the
determination of Pyritinol dihydrochloride.
![Page 4: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/4.jpg)
This part includes a general introduction about the chemistry of pyritinol dihydrochloride,mode of action.
A review on the reported methods used for pyritinol dihydrochloride quantitative determination.
![Page 5: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/5.jpg)
Section(A): Determination of pyritinol
dihydrochloride in presence of its precursor and its degradation
product by derivative spectrophotometry.
![Page 6: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/6.jpg)
The structure of pyritinol
dihydrochloride:-
How to obtain the precursor ?
How to obtain the degradation product?
N NCH3
HOS -S
CH3
OH
OH
2HCl.. H2O
HO
N N NCH3
HOS -S
CH3
OH
OHHO
CH3
HO
HO
Zn pd. /1NHCl
1hr2
SH.HCl
mol.wt 221
N N NCH3
HOS -S
CH3
.2HCl
OHHO
CH3
HO
HO
H2O2 30% v/v
leave 1hr.at room temp.
2SO3H.HCl
OH
mol.wt 269
![Page 7: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/7.jpg)
I.A.1First derivative spectrophotometric
determination of pyritinol dihydrochloride in presence of its
precursor and its degradation product.
![Page 8: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/8.jpg)
Figure ( 1 ): Absorption spectra of Pyritinol dihydrochloride 20 µg. ml-1 ,)———(
precursor 14 µg. ml-1 (— — — — ) and degradation product 6 µg. ml-1 (--------- ) Using 0.1N hydrochloric acid as a solvent
![Page 9: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/9.jpg)
Figure ( 2 ): First – derivative absorption spectra of Pyritinol dihydrochloride 20 µg. ml-1 (———), precursor 14 µg. ml-1 (— — — — ) and degradation product 6 µg. ml-1 (---------- ). Using 0.1N hydrochloric acid as a solvent
![Page 10: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/10.jpg)
Figure ( 3 ): First – derivative absorption spectra of 6-22 µg. ml-1 Pyritinol dihydrochloride
![Page 11: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/11.jpg)
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0 5 10 15 20 25
Concenteration g.ml-1
Pe
ak
am
plit
ud
e
Figure (4): Linearity of the peak amplitude of the first derivative at 284.4nm to the corresponding concentration of pyritinoldihydrochloride.
![Page 12: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/12.jpg)
I.A.2.Derivative ratio zero crossing method for the determination of pyritinol dihydrochloride in presence of its
precursor and its degradation product .
![Page 13: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/13.jpg)
A
) pyritinol(/deg.prod.(
Figure ( 5 ): Zero order of ratio spectra of 6-20 µg. ml-1
pyritinol.2HCl / deg. Product (———)and 14 µg. ml-1 precursor/ deg. Product (-------) using 6 µg. ml-1 deg. product as a divisor.
![Page 14: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/14.jpg)
dA)pyritinol.2H
Cl/ deg. prod.(/dλ
Figure ( 5 ): First order of ratio spectra of 6-20µg. ml-1
pyritinol.2HCl / deg. Product (———)and 14 µg. ml-1 precursor/ deg. Product (-------) using 6 µg. ml-1 deg. product as a divisor.
![Page 15: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/15.jpg)
-12
-10
-8
-6
-4
-2
0
0 5 10 15 20 25
Concenteration g.ml-1
Pea
k am
pli
tud
e
Figure (7): Linearity of the peak amplitude of the first derivative of
the ratio spectra at 316 nm to the corresponding
concentration pyritinol dihydrochloride.
![Page 16: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/16.jpg)
Table (I): determination of pyritinol dihydrochloride in laboratory prepared mixtures by the proposed procedures.
Concentration (µg/ml) Percentage % First derivative spectrophotometry
Derivative ratio- zero crossing
Pyritinol.2HCl
Precursor
Deg.produtt Pyritiol.2HCl
Precursor Deg.product
Recovery % Recovery %
Pyritinol.2HCl Pyritinol. 2HCl
17.00 1.00 2.00 85% 5% 10% 98.23% 98.56%
16.00 2.00 2.00 80% 10% 10% 100.77% 100.23%
15.00 2.00 3.00 75% 10% 15% 99.91% 99.86%
14.00 2.00 4.00 70% 10% 20% 99.05% 99.98%
13.00 1.00 5.00 65% 5% 25% 100.91% 100.97%
12.00 2.00 6.00 60% 10% 30% 102.07% 101.95%
11.00 2.00 7.00 55% 10% 35% 99.83% 99.97%
10.00 2.00 8.00 50% 10% 40% 100.39% 100.71%
9.00 2.00 9.00 45% 10% 45% 100.34% 100.94%
8.00 2.00 10.00 40% 10% 50% 100.12% 99.98%
Mean 100.15 100.11
S.D. 0.615 0.572
![Page 17: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/17.jpg)
Table (II): Determination of pyritinol dihydrochloride in encephabol tablets by the proposed procedures.
* Average of six determinations. **Spectrophotometric method
Encephabol tablets claimed to contain 200 mgBatch number
First derivative spectro photometry
Derivative ratio-zero crossing
Compendial method**
% Found
% Found
Recovery % ± S.D.*
19578 99.27 99.43 99.36 ± 0.421
19357 99.61 99.85 99.72 ± 0.854
19722 99.93 100.41 99.91 ± 0.739
![Page 18: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/18.jpg)
Table (III): Statistical comparison for the results obtained by the proposed method and the compendial method for the analysis of pyritinol dihydrochloride in pure powder form.
The figures in parenthesis are the corresponding tabulated values at P=0.05.*Spectrophotometric method
First derivative spectrophotometry
Derivative ratio- zero crossing method.
Compendial method*
Pyritinol dihydrochloride
Pyritinol dihydrochloride Pyritinoldihydrochloride
Mean 100.364 99.922 99.061
S.D. 1.497 1.172 1.053
Variance 2.241 1.375 1.109
N 9 8 6
F test 2.021 (4.82) 1.24 (4.88)
Student’s t test 1.84 (2.160) 1.42 (2.179)
![Page 19: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/19.jpg)
Table (IV): Results of application of standard addition to the determination of pyritinol dihydrochloride by the proposed
method.
Batch number
Standard added(mg.ml-1)
First derivative spectro photometry
Derivative ratio-zero crossing
Pyritinol dihydrochloride
Recovery % of added
Recovery % of
added 19578 0.10
0.150.20
101.3199.3298.75
101.0099.06
100.92
Mean ± S.D. 99.79 ± 1.344 100.33 ±1.097
19357 0.100.150.20
98.9299.47
100.82
99.8799.36
100.56
Mean ± S.D. 99.73 ± 0.977 99.93 ± 0.602
19722 0.100.150.20
98.7598.75
100.82
99.38100.2698.82
Mean ± S.D. 99.44 ± 1.195 99.48± 0.725
![Page 20: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/20.jpg)
Section (B): Determination of pyritinol dihydrochloride in presence of its precursor and its degradation product by
densitometric method.
![Page 21: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/21.jpg)
Figure (12): TLC chromatogram of pyritinol dihydrochloride, its degradation product and its precursor .
A= Pyritinol dihydrochloride. Rf = 0.4
B= Degradation product. Rf = 0.5
C= Precursor. Rf = 0.66
Developing system: n-butanol : acetic acid : water (4:1:1 v/v/v).
![Page 22: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/22.jpg)
Figure ) 13 (:
Scanning profile of TLCchromatogram of pyritinol
dihydrochloride at 300 nm.
![Page 23: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/23.jpg)
0
1
2
3
4
5
6
7
8
0 5 10 15 20
Concentration g.spot-1
Inte
gra
ted
pe
ak
are
a
( x
10
-4)
Figure (14): Linearity of the area under the peak to the corresponding concentration of pyritinol dihydrochloride.
![Page 24: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/24.jpg)
Table (V): Determination of pyritinol dihydrochloride in laboratory prepared mixtures by the proposed procedures.
Concentration (µg/ml) Percentage % Densitometric method
Pyritinol.2HCl Precursor Deg.product Pyritinol.2HCl Precursor Deg.productRecovery %
Pyritinol 2.HCl
900 50 100 90 5 10 99.98%
800 50 150 80 5 15 99.80%
700 100 200 70 10 20 100.06%
600 100 300 60 10 30 100.75%
500 100 400 50 10 40 98.96%
400 100 500 40 10 50 99.86%
300 100 600 30 10 60 99.51%
Mean 99.84
S.D. 0.54
![Page 25: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/25.jpg)
Table (VI): Determination of pyritinol dihydrochloride in encephabol tablets by the proposed procedures.
* Average of four determinations. **Spectrophotometric method.
Encephabol tablets claimed to contain 200 mg
Batch number
Densitometric method Compendial method**
% Found
Recovery % ± S.D.*
19578 99.63 99.36 ± 0.421
19357 99.22 99.72 ± 0.854
19722 100.15 99.91 ± 0.739
![Page 26: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/26.jpg)
Table (VII): Statistical comparison for the results obtained by the proposed method
and the compendial method for the analysis of pyritinol dihydrochloride in pure powder
form.
The figures in parenthesis are the corresponding tabulated values at P=0.05 (36).*Spectrophotometric method
Densitometric method. Compendial method*
Pyritinol dihydrochloride Pyritinol dihydrochloride
Mean 99.908 99.061
S.D. 0.848 1.053
Variance 0.719 1.109
N 8 6
F test 1.542(4.362)
Student’s t test 1.67(2.179)
![Page 27: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/27.jpg)
Table (VIII): Results of application of standard addition to the determination of pyritinol dihydrochloride by the proposed method.
Batch number
Standard added(mg.ml-1)
Densitometric method
Pyritinol dihydrochloride
Recovery % of added
19578 1.001.502.00
99.51100.3398.79
Mean ± S.D. 99.54± 0.770
19357 1.001.502.00
100.6299.4799.31
Mean ± S.D. 99.80 ± 0.714
19722 1.001.502.00
99.32100.6999.03
Mean ± S.D. 99.68 ± 0.886
![Page 28: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/28.jpg)
Table (IX) : Assay parameters and method validation
* RSD%a , RSD%b the intraday, interday respectively (n=5) relative standard deviation of concentrations ( 12- 14µg/ml) for first derivative and derivative methods, and concentrations ( 7-9µg/spot) for densitometric method.
Parameter First Derivative spectrophotometery
Derivative ratio – zero crossing
Densitometric method
Pyritinol dihydrochloride
Pyritinol dihydrochloride
Pyritinol dihydrochloride
Range (µg.ml-1) 6-22 6-20 1-15 (µg.spot-1)
Slope 0.0143 -0.4751 0.439
Intercept 0.0082 -0.071 0.0844
Mean 100.364 99.922 99.908
S.D. 1.497 1.172 0.848
Variance 2.241 1.375 0.719
Coff. of variation 1.491 1.173 0.848
Correl. Coef.(r) 0.9994 0.9995 0.9998
* RSD%a 0.128- 0.203 0.132 – 0.197 0.378 –0.521
*RSD %b 0.136 –0.184 0.141 –0.175 0.554 –0.673
![Page 29: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/29.jpg)
Section (C): Oxidation – reduction titrimetric method for the determination of pyritinol dihydrochloride in presence of its
degradation product.
![Page 30: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/30.jpg)
The proposed reaction mechanism :
3Br2 + 6 es 6 Br - (x10)
R-S-S-R + 6H2O 2 RSO3H + 10 H + + 10 es(x6)
Add the the two equations
60 Br -30 Br2 + 6 R-S-S-R + 36 H2O 12 RSO3H + 60 H+ +
Therfore 30Br2 = 6 R-S-S-R
Since BrO3 - + 5Br - +6 H+ 3 Br2 + 3 H2O
Therfore 10 K BrO3 / K Br = 30 Br2 = 6 R-S-S-R
1M K BrO3 / K Br = 6 R-S-S-R / 10
1 ml N/40 K BrO3 / K Br = 6 R-S-S-R / (6x10x40x1000)
= 441/(400x1000) = 1.1025 mg
Where R-S-S-R =
N NCH3
HOS -S
CH3
OH
OH
2HCl.. H2O
HO
![Page 31: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/31.jpg)
Table (XI) : Determination of pyritinol dihydrochloride in laboratory prepared mixtures by the proposed method .
Weight (mg) Percentage Titrimetricmethod
Pyritinol dihydrochlorid
e
Degradation product
Pyritinol dihydrochlorid
e
Degradation product
Recovery %
Pyritinol dihydrochloride
15 5 75% 25% 101.04
10 10 50% 50% 100.12
5 15 25% 75% 101.79
Mean 101.13
S.D. 0.740
![Page 32: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/32.jpg)
Table (XII): Determination of pyritinol dihydrochloride in encephabol tablets by the proposed procedures.
* Average of six determinations. **Spectrophotometric method
Encephabol tablets claimed to contain 200 mgBatch number
Titrimetric method Compendial method**
% Found
Recovery % ± S.D.*
19578 101.50 99.36 ± 0.421
19357 100.13 99.72 ± 0.854
19722 98.59 99.91 ± 0.739
![Page 33: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/33.jpg)
Table (XIII): Statistical comparison for the results obtained by the proposed method and the compendial method for the analysis of pyritinol dihydrochloride in pure powder form.
The figures in parenthesis are the corresponding tabulated values at P=0.05. *Spectrophotometric method
Titrimetric method Compendial method*
Pyritinol dihydrochloride Pyritinol dihydrochloride
Mean 99.928 99.061
S.D. 1.566 1.053
Variance 2.452 1.109
N 6 6
F test 2.211 (5.05)
Student’s t test 1.115 (2.228)
![Page 34: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/34.jpg)
Table (XIV): Results of application of standard addition to the determination of pyritinol dihydrochloride by the proposed method.
Batch number
Standard added(mg.ml-1)
Titrimetric method
Pyritinol dihydrochloride
Recovery % of added
19578 1.001.502.00
99.32100.4098.23
Mean ± S.D. 99.31± 1.085
19357 1.001.502.00
101.5698.79
100.61
Mean ± S.D. 100.32 ± 1.407
19722 1.001.502.00
99.13101.5099.06
Mean ± S.D. 99.89 ± 1.388
![Page 35: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/35.jpg)
Table (XV) : Assay parameters and method validation
* RSD%a , RSD%b the intraday, interday respectively (n=3) relative standard deviation of concentrations ( 5 – 10 mg) .
ParameterTitrimetric method
Pyritinol dihydrochloride
Range (mg) 1 – 20
Mean 99.928
S.D. 1.566
Variance 2.452
Coff. of variation 1.567
* RSD%a 0.461 – 0.511
*RSD %b 0.673 – 0.562
![Page 36: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/36.jpg)
Part IIStability indicating colorimetric method for the
determination of piracetam.
![Page 37: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/37.jpg)
- This part includes a general introduction about the chemistry and mode of action of piracetam.
- A review on the reported methods for its quantitative determination.
-Stability indicating colorimetric method for the determination of piracetam using ninhydrin reagent.
![Page 38: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/38.jpg)
-Structure of piracetam.
N
O
O
NH2
-The proposed reaction mechanism for preparing the degradation product
N
O
O
NH21 N NaOH
reflux 1 hr
N
O
O
OH
+ NH3
![Page 39: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/39.jpg)
-The proposed reaction mechanism of piracetam with ninhydrin:
N
O
O
NH2
O
OOH
OH N
O
O
N
O
O
+
+ 2 H2O
![Page 40: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/40.jpg)
Figure (15): Absorption spectra of
Piracetam in water 100 µg. ml-1 ).……(
Ninhydrin 4( % _ _ _ _ _ )
Colored product 30 µg. ml-1 (_______.)
![Page 41: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/41.jpg)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0 2 4 6 8 10
Volume (ml) of ninhydrin solution
Ab
so
rba
nc
e
Figure (20): Effect of volume (ml)of ninhydrin solution on the
absorbance of the colored product.
![Page 42: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/42.jpg)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0 2 4 6 8
pH
Ab
so
rba
nc
e
Figure (21): Effect of pH on the absorbance of the colored product.
![Page 43: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/43.jpg)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0 5 10 15 20 25 30
Heating time in min.
Ab
so
rba
nc
e
Figure (22): Effect of heating time on the absorbance of the colored product.
![Page 44: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/44.jpg)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0 0.5 1 1.5
Volume (ml) of pyridine
Ab
so
rba
nc
e
Figure (23): Effect of volume (ml) of pyridine on the absorbance of the colored product.
![Page 45: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/45.jpg)
Figure (18): Absorption spectra of colored product ( piracetam with ninhydrin) 10-50 μg. ml-1
![Page 46: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/46.jpg)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 20 40 60
Concentration g.ml-1
Ab
so
rba
nc
e
Figure (19): Linearity of the absorbance of the colored product of
piracetam with ninhydrin to the corresponding
concentration of piracetam.
![Page 47: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/47.jpg)
Concentration (µg/ml) Percentage % NinhydrinMethod
Piracetam Degradation product
PiracetamDegradation product
Recovery %
Piracetam
45 5 90% 10% 98.32
40 10 80% 20% 99.24
35 15 70% 30% 101.06
30 20 60% 40% 100.25
25 25 50% 50% 98.89
20 30 40% 60% 101.70
15 35 30% 70% 98.88
10 40 20% 80% 100.54
Mean 99.86
S.D. 1.201
Table (XVI): Determination of piracetam in laboratory prepared mixtures by the proposed
procedures.
![Page 48: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/48.jpg)
Table (XVII): Determination of piracetam in nootropil and stimulan by the proposed procedures.
* Average of six determinations.
**Titrimetric method
Commercial Name Dosage form Batch number
Ninhydrin method Compendial method**
% Found
Recovery % ± S.D.*
Nootropil
TabletCapsuleAmpoule
Syrup
001108001108501106600114
99.61 99.9398.95 98.45
98.63 ± 1.2799.32 ± 0.9398.21 ± 1.3198.11 ± 1.54
Stimulan
TabletCapsuleAmpoule
Syrup
1537166815941653
98.80 99.75 99.53
100.42
97.90 ± 0.9898.95 ± 1.3498.23 ± 1.2798.62 ± 1.47
![Page 49: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/49.jpg)
Table (XVIII): Statistical comparison for the results obtained by the proposed method and the compendial method for the
analysis of piracetam in pure powder form.
The figures in parenthesis are the corresponding tabulated values at P=0.05.*Titrimetric method
Ninhydrin method Compendial method*
Piracetam Piracetam
Mean 99.746 98.892
S.D. 1.171 1.023
Variance 1.371 1.046
N 9 6
F test 1.309 (4.82)
Student’s t test 1.451 (2.160)
![Page 50: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/50.jpg)
Table (XIX): Results of application of the standard addition to the
determination of piracetam by the proposed method.
CommercialName
Batchnumbe
r
Standardadded
mg.ml -1
Ninhydrinmethod
Batchnumber
Standardadded
mg.ml -1
NinhydrinMethod
Piraceta
m
Recovery%of added
Piraceta
m
Recovery %of added
Nootropil
001108tablet
mean± S.D.
0.500.751.00
99.3298.23100.4099.31 ± 1.085
501106ampoule
mean±S.D.
0.500.751.00
100.14100.50100.16
100.26±0.202
001108capusl
e
mean± S.D.
0.500.751.00
101.50102.5099.79101.26 ±1.370
600114syrup
mean±S.D.
0.500.751.00
100.0099.6398.87
99.60±0.576
Stimulan 1537tablet
mean± S.D.
0.500.751.00
99.1399.9398.70
98.25±0.620
1594ampoule
mean±S.D.
0.500.751.00
99.2199.74
101.21100.05±1.036
1668capsul
e
mean± S.D.
0.500.751.00
98.5698.7198.29
98.52± 0.210
1653syrup
mean±S.D.
0.500.751.00
99.6898.9199.93
99.50±0.530
![Page 51: Analytical study on certain drugs which treat brain agency and deterioration](https://reader036.vdocuments.mx/reader036/viewer/2022070411/56814878550346895db58302/html5/thumbnails/51.jpg)
Table (XX) : Assay parameters and method validation
* RSD%a , RSD%b the intraday, interday respectively (n=5) relative standard deviation of concentrations (20-30 µg/ml) for piracetam
Parameter Ninhydrin method
Piracetam
Range (µg.ml-1) 10-50
Slope 0.0185
Intercept 0.0246
Mean 99.746
S.D. 1. 1707
Variance 1.37
Coff. of variation 1.173
Correl. Coef.(r) 0.9993
* RSD%a 0.223-0.317
*RSD %b 0.421-0.584